Bizarre Patents
A haircutting appliance comprises an enclosed housing having a hollow handle connecting the housing to a vacuum source to carry away cut hairs from a subject's head.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187606 | HPV antigen fusion protein vaccine compositions and uses thereof The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmace... | 05/29/2012 |
| 8173134 | ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations i... | 05/08/2012 |
| 8168194 | Fusion proteins comprising CD4 minimal modules and human immunodeficiency virus (HIV) Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatme... | 05/01/2012 |
| 8147843 | CD95L or trail fusion proteins The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric co... | 04/03/2012 |
| 8147842 | Mutant luciferase An object of the present invention is to provide a mutant luciferase having luciferase activity with an altered emission spectrum. A specific amino acid residue(s) is substituted in a luciferase derived from Cypridina noctiluca and then the resulting mutant l... | 04/03/2012 |
| 8142791 | Multi-modal cancer therapy using viral hitch-hiking The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocy... | 03/27/2012 |
| 8142790 | Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells The present invention provides novel methods for targeting an antigen to a dendritic cell using an antibody linked to the antigen. The present invention further provides methods of inducing or enhancing an immune response and methods of immunization using an antibod... | 03/27/2012 |
| 8137674 | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fu... | 03/20/2012 |
| 8133491 | Compositions and methods for treatment of hyperplastic disorders A method for treating a subject includes injecting a therapeutic amount of a composition derived from a cobra toxin into a tissue of the subject in an amount sufficient to diminish at least one symptom of a hyperplastic disorder. ... | 03/13/2012 |
| 8084036 | Broad spectrum anti-viral therapeutics and prophylaxis The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeuti... | 12/27/2011 |
| 8084037 | Recombinant parainfluenza virus expression systems and vaccines The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or... | 12/27/2011 |
| 8080254 | OB fusion protein compositions and methods The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative... | 12/20/2011 |
| 8080253 | Chimeric VEGF peptides Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the ep... | 12/20/2011 |
| 8034351 | Mucin fusion polypeptide vaccines, compositions and methods of use thereof The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins. ... | 10/11/2011 |
| 8008257 | ANF fusion proteins A fusion protein comprising an arterial natriuretic factor (ANF) amino acid sequence linked to an albumin amino acid sequence by one or more peptide bonds is provided. The ANF amino acid sequence may be linked to the N-terminal, the C-terminal, or both the N-termina... | 08/30/2011 |
| 8007813 | CD95-Fc fusion proteins The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain. ... | 08/30/2011 |
| 7998485 | Sialoadhesin-related compositions and methods Methods of delivering a cargo moiety to a cell is provided according to embodiments of the present invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin bindin... | 08/16/2011 |
| 7993652 | Immunoprotective influenza antigen and its use in vaccination The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a no... | 08/09/2011 |
| 7976845 | Human cytomegalovirus immunotherapy An isolated protein construct comprising a polyepitope derived from multiple human cytomegalovirus protein antigen epitopes conjugated to an extracellular domain of glycoprotein B, which isolated protein is capable of eliciting a cytotoxic T-lymphocyte immune respon... | 07/12/2011 |
| 7976844 | Fusion proteins of The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera ... | 07/12/2011 |
| 7959925 | Trimeric OX40-immunoglobulin fusion protein and methods of use Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition ... | 06/14/2011 |
| 7947651 | Secreted frizzled related protein, sFRP, fragments and methods of use thereof The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt prot... | 05/24/2011 |
| 7935350 | Ii-key/Her-2/neu hybrid cancer vaccine Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the n... | 05/03/2011 |
| 7927603 | Recombinant fusion-enzyme with repair activity on DNA lesions produced by UV radiation; its usage, preparation and purification method; a method to stabilize enzymes and treatment methods A recombinant fusion enzyme repairs DNA damaged by UV radiation, and the method of preparing recombinant fusion enzyme. The method includes the fusion of an enzyme coded by a gene isolated from Micrococcus luteus and a stabilizing peptide having the amino aci... | 04/19/2011 |
| 7927602 | Fas ligand-avidin/streptavidin fusion proteins This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeri... | 04/19/2011 |
| 7923015 | Methods for direct visualization of active synapses A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation... | 04/12/2011 |
| 7923016 | Engineered CXCL12 α locked dimer polypeptide The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS. ... | 04/12/2011 |
| 7914796 | Engineered cleavage half-domains Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising these polynucleotides and/or fusion ... | 03/29/2011 |
| 7897153 | Chimera of human IgE receptor α-chain and avian constant immuno-globulin domains for the determination of serum IgE The instant application inter alia relates to chimeric fusion constructs comprising the extracellular portion of human FcεRIα and at least one avian constant immunoglobulin domain and the use thereof for in vitro diagnostic purposes. ... | 03/01/2011 |
| 7897152 | Viral chemokine-antigen fusion proteins The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immuno... | 03/01/2011 |
| 7892561 | Neutralizing GDF8 epitope-based growth enhancing vaccine The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the... | 02/22/2011 |
| 7892560 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the ... | 02/22/2011 |
| 7867498 | Polypeptide carrier protein The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These v... | 01/11/2011 |
| 7820174 | T cell receptors and related materials and methods of use The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner... | 10/26/2010 |
| 7815911 | Compositions and methods for treating infection Compositions and methods for treating a Yersinia pestis (Y. pestis) infection are provided. Compositions and methods of for inducing an immune response in a subject are provided. Composition can include a YadC polypeptide. ... | 10/19/2010 |
| 7811577 | Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of t... | 10/12/2010 |
| 7811578 | Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be ... | 10/12/2010 |
| 7807174 | Class of therapeutic protein based molecules The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeuti... | 10/05/2010 |
| 7803383 | Method of treatment comprising administration of a cytokine antagonist molecule This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression... | 09/28/2010 |
| 7794727 | Polyvalent chimeric OspC vaccinogen and diagnostic antigen A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be as... | 09/14/2010 |
